Sarepta Gene Therapy Setbacks

News

Sarepta, Gene Therapy

Sarepta's Setback Deepens With Another Gene Therapy Fatality

Sarepta Therapeutics (NASDAQ:SRPT) shares plummeted on Friday following reports of a third patient death linked to its gene therapy pipeline this year, further clouding investor confidence despite the company’s recent efforts to provide clarity on its restructuring and FDA label plans.

· 2d · on MSN

Sarepta says it won't comply with FDA request to stop shipping gene therapy Elevidys

STAT · 2d

Pharmalittle: We’re reading about a GSK setback, another Sarepta gene therapy death, and more

4don MSN

Sarepta to cut 500 jobs after gene therapy setback, shares jump

Sarepta Therapeutics said on Wednesday it would lay off 36% of its workforce, or about 500 employees, after the recent deaths of two patients who had received its gene therapy Elevidys. Its shares ...

STAT2dOpinion

We are mothers of Duchenne patients. Recent setbacks with Sarepta must not stop progress

As mothers of children with this disease, we have wept helplessly in recent months as friends — fellow members of a club we ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

News

Sarepta, Gene Therapy

Trending now